BluePrint Archives - Agendia Inc.

MammaPrint and BluePrint Molecular Diagnostics Using Targeted RNA Next-Generation Sequencing Technology
Gallery
MammaPrint and BluePrint Molecular Diagnostics Using Targeted RNA Next-Generation Sequencing Technology

BluePrint, Evidence, Journal of Molecular Diagnostics, MammaPrint, Mittempergher, Test Development, Test Development and Clinical Validation

MammaPrint and BluePrint Molecular Diagnostics Using Targeted RNA Next-Generation Sequencing Technology

PUBLICATION: Journal of Molecular Diagnostics September 2019 Volume 21, Issue Read More

kevin2020-06-15T17:49:00-07:00September 1st, 2019|BluePrint, Evidence, Journal of Molecular Diagnostics, MammaPrint, Mittempergher, Test Development, Test Development and Clinical Validation|

Strong Impact of MammaPrint and BluePrint on Treatment Decisions in Luminal Early Breast Cancer: Results of the WSG-PRIMe Study
Gallery
Strong Impact of MammaPrint and BluePrint on Treatment Decisions in Luminal Early Breast Cancer: Results of the WSG-PRIMe Study

BluePrint, Breast Cancer Research Treatment, Clinical Validation, Evidence, MammaPrint, Wuerstlein

Strong Impact of MammaPrint and BluePrint on Treatment Decisions in Luminal Early Breast Cancer: Results of the WSG-PRIMe Study

PUBLICATION: Breast Cancer Res Treat. (2019) 175: 389. https://doi.org/10.1007/s10549-018-05075-x. AUTHORS: Read More

kevin2020-06-15T17:56:37-07:00June 1st, 2019|BluePrint, Breast Cancer Research Treatment, Clinical Validation, Evidence, MammaPrint, Wuerstlein|

Estrogen Receptor Variants in ER-Positive Basal-Type Breast Cancers Responding to Therapy Like ER-Negative Breast Cancers
Gallery
Estrogen Receptor Variants in ER-Positive Basal-Type Breast Cancers Responding to Therapy Like ER-Negative Breast Cancers

BluePrint, Evidence, Groenendijk, npj Breast Cancer, Test Development and Clinical Validation

Estrogen Receptor Variants in ER-Positive Basal-Type Breast Cancers Responding to Therapy Like ER-Negative Breast Cancers

PUBLICATION: npj Breast Cancer; volume 5, Article number: 15 (2019). Read More

kevin2020-06-15T17:56:43-07:00April 18th, 2019|BluePrint, Evidence, Groenendijk, npj Breast Cancer, Test Development and Clinical Validation|

Reclassification of Early Stage Breast Cancer Into Treatment Groups by Combining the Use of Immunohistochemistry and Microarray Analysis
Gallery
Reclassification of Early Stage Breast Cancer Into Treatment Groups by Combining the Use of Immunohistochemistry and Microarray Analysis

BluePrint, Evidence, Grant, South African Journal of Science, Test Development and Clinical Validation

Reclassification of Early Stage Breast Cancer Into Treatment Groups by Combining the Use of Immunohistochemistry and Microarray Analysis

PUBLICATION: Vol 115 No 3/4 (2019): South African Journal of Read More

kevin2020-06-15T17:58:57-07:00March 27th, 2019|BluePrint, Evidence, Grant, South African Journal of Science, Test Development and Clinical Validation|

AACR BluePrint HER2 Poster 2612
Gallery
AACR BluePrint HER2 Poster 2612

BluePrint, Evidence, iSPY, Posters/ Presentations

AACR BluePrint HER2 Poster 2612

AUTHORS: Pei Rong Evelyn Lee, Zelos Zhu, Denise Wolf, Christina Read More

kevin2020-06-15T17:59:33-07:00April 18th, 2018|BluePrint, Evidence, iSPY, Posters/ Presentations|

Copy Number Profiling of MammaPrint Genes Reveals Association with the Prognosis of Breast Cancer Patients
Gallery
Copy Number Profiling of MammaPrint Genes Reveals Association with the Prognosis of Breast Cancer Patients

BluePrint, Evidence, Fatima, MammaPrint, Test Development

Copy Number Profiling of MammaPrint Genes Reveals Association with the Prognosis of Breast Cancer Patients

PUBLICATION: J Breast Cancer. 2017 Sep;20(3):246-253. English. Published online Sep Read More

kevin2020-06-15T18:02:53-07:00September 22nd, 2017|BluePrint, Evidence, Fatima, MammaPrint, Test Development|

Pertuzumab/Trastuzumab/CT Versus Trastuzumab/CT Therapy for HER2+ Breast Cancer: Results from the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)
Gallery
Pertuzumab/Trastuzumab/CT Versus Trastuzumab/CT Therapy for HER2+ Breast Cancer: Results from the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)

Ann Surg Oncol., Annals of Surgical Oncology, Beitsch, BluePrint, Evidence, Pre-surgical Clinical Validation

Pertuzumab/Trastuzumab/CT Versus Trastuzumab/CT Therapy for HER2+ Breast Cancer: Results from the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)

PUBLICATION: Ann Surg Oncol. 2017 Sep;24(9):2539-2546. doi: 10.1245/s10434-017-5863-x. AUTHORS: Peter Read More

kevin2020-06-15T18:40:59-07:00April 26th, 2017|Ann Surg Oncol., Annals of Surgical Oncology, Beitsch, BluePrint, Evidence, Pre-surgical Clinical Validation|

Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping
Gallery
Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping

Annals of Surgical Oncology, BluePrint, Evidence, Pre-surgical Clinical Validation, Whitworth

Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping

PUBLICATION: Annals of Surgical Oncology; March 2017, Volume 24, Issue Read More

kevin2020-06-15T18:44:13-07:00October 21st, 2016|Annals of Surgical Oncology, BluePrint, Evidence, Pre-surgical Clinical Validation, Whitworth|

Genomic Impact of Neoadjuvant Therapy on Breast Cancer: Incomplete Response is Associated with Altered Diagnostic Gene Signatures
Gallery
Genomic Impact of Neoadjuvant Therapy on Breast Cancer: Incomplete Response is Associated with Altered Diagnostic Gene Signatures

Ann Surg Oncol., Annals of Surgical Oncology, Beitsch, BluePrint, Evidence, Pre-surgical Clinical Validation

Genomic Impact of Neoadjuvant Therapy on Breast Cancer: Incomplete Response is Associated with Altered Diagnostic Gene Signatures

PUBLICATION: Ann Surg Oncol (2016) 23: 3317. https://doi.org/10.1245/s10434-016-5329-6. AUTHORS: Peter Read More

kevin2020-06-15T18:47:08-07:00July 6th, 2016|Ann Surg Oncol., Annals of Surgical Oncology, Beitsch, BluePrint, Evidence, Pre-surgical Clinical Validation|

Impact of Tumor Size on Probability of Pathologic Complete Response After Neoadjuvant Chemotherapy
Gallery
Impact of Tumor Size on Probability of Pathologic Complete Response After Neoadjuvant Chemotherapy

Annals of Surgical Oncology, Baron, BluePrint, Evidence, Pre-surgical Clinical Validation

Impact of Tumor Size on Probability of Pathologic Complete Response After Neoadjuvant Chemotherapy

PUBLICATION: Ann Surg Oncol (2016) 23: 1522. https://doi.org/10.1245/s10434-015-5030-1. AUTHORS: Paul Read More

kevin2020-06-15T18:50:10-07:00May 1st, 2016|Annals of Surgical Oncology, Baron, BluePrint, Evidence, Pre-surgical Clinical Validation|

agendia_logo_stacked_white_po

Quick Links

Our Tests
Resources
Landmark Trials
Order A Test
For Patients

Legal

Privacy Policy
Legal & Compliance
Terms & Conditions
Licenses & Accreditations
Code of Conduct

Contact

For the US, Puerto Rico, Canada
and South America
Agendia Inc. USA, 22 Morgan, Irvine, CA 92618
(888) 321-2732
customercare@agendia.com

For outside the Americas
Agendia NV, Radarweg 60, 1043 NT Amsterdam, The Netherlands
+31 (0)20 462 1510
customerservice@agendia.com

©2023 Agendia. All rights reserved. MammaPrint and Blueprint are registered trademarks of Agendia, Inc.